Marrone Bio Innovations (MBII) 10-Q 9 Nov 20 2020 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2020	Nov. 06, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity File Number	001-36030
Entity Registrant Name	Marrone Bio Innovations, Inc.
Entity Central Index Key	0001441693
Entity Tax Identification Number	20-5137161
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1540 Drew Avenue
Entity Address, City or Town	Davis
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95618
City Area Code	(530)
Local Phone Number	750-2800
Title of 12(b) Security	Common Stock, $0.00001 par value
Trading Symbol	MBII
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		152,477,013

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 8,971	$ 6,252
Accounts receivable	6,827	5,925
Inventories, net	6,193	8,149
Prepaid expenses and other current assets	2,016	1,390
Total current assets	24,007	21,716
Property, plant and equipment, net	12,789	13,260
Right of use assets, net	3,977	4,567
Intangible assets, net	22,079	23,842
Goodwill	6,740	6,764
Restricted cash	1,560	1,560
Other assets	911	1,008
Total assets	72,063	72,717
Current liabilities:
Accounts payable	1,985	3,379
Accrued liabilities	13,101	12,467
Deferred revenue, current portion	541	427
Lease liability, current portion	981	913
Debt, current portion, net	6,333	3,899
Total current liabilities	22,941	21,085
Deferred revenue, less current portion	1,688	1,986
Lease liability, less current portion	3,303	3,970
Debt, less current portion, net	11,367	11,847
Debt due to related parties	7,300	7,300
Other liabilities	2,359	2,971
Total liabilities	48,958	49,159
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at September 30, 2020 and December 31, 2019
Common stock: $0.00001 par value; 250,000 shares authorized, 152,475 and 139,526 shares issued and outstanding as of September 30, 2020 and December 31, 2019	1	1
Additional paid in capital	359,710	344,206
Accumulated deficit	(336,606)	(320,649)
Total stockholders’ equity	23,105	23,558
Total liabilities and stockholders’ equity	$ 72,063	$ 72,717

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	152,475,000	139,526,000
Common stock, shares outstanding	152,475,000	139,526,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 8,828	$ 6,966	$ 30,656	$ 22,679
Cost of product revenues	3,826	3,381	12,701	10,298
Gross profit	5,002	3,585	17,955	12,381
Operating Expenses:
Research, development and patent	3,112	3,760	8,658	10,336
Selling, general and administrative	7,335	9,598	22,406	21,876
Total operating expenses	10,447	13,358	31,064	32,212
Loss from operations	(5,445)	(9,773)	(13,109)	(19,831)
Other income (expense):
Interest expense	(405)	(355)	(1,073)	(1,014)
Loss on modification of warrants		(1,564)		(1,564)
Loss on issuance of new warrants		(4,751)	(1,391)	(4,751)
Change in fair value of contingent consideration	(200)		(563)
Other income (expense), net	24	77	296	126
Total other income (expense), net	(581)	(6,593)	(2,731)	(7,203)
Loss before taxes	(6,026)	(16,366)	(15,840)	(27,034)
Income Taxes	(37)		(117)
Net loss	$ (6,063)	$ (16,366)	$ (15,957)	$ (27,034)
Basic and diluted net loss per common share:	$ (0.04)	$ (0.14)	$ (0.11)	$ (0.24)
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:	150,233,000	116,186,000	146,840,000	112,553,000
Product [Member]
Revenues:
Total revenues	$ 8,697	$ 6,859	$ 30,295	$ 22,342
License [Member]
Revenues:
Total revenues	$ 131	$ 107	$ 361	$ 337

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholder's Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2018	$ 1	$ 296,409	$ (283,474)	$ 12,936
Beginning balance, shares at Dec. 31, 2018	110,691,000
Net loss			(3,917)	(3,917)
Share-based compensation		558		558
Issuance of common stock in connection with Pro Farm acquisition, shares
Settlement of restricted stock units, shares
Ending balance, value at Mar. 31, 2019	$ 1	296,967	(287,391)	9,577
Ending balance, shares at Mar. 31, 2019	110,691,000
Beginning balance, value at Dec. 31, 2018	$ 1	296,409	(283,474)	12,936
Beginning balance, shares at Dec. 31, 2018	110,691,000
Net loss				(27,034)
Ending balance, value at Sep. 30, 2019	$ 1	335,064	(310,508)	24,557
Ending balance, shares at Sep. 30, 2019	133,404,000
Beginning balance, value at Mar. 31, 2019	$ 1	296,967	(287,391)	9,577
Beginning balance, shares at Mar. 31, 2019	110,691,000
Net loss			(6,751)	(6,751)
Net settlement of options		42		42
Net settlement of options, shares	34,000
Share-based compensation		606		606
Employee stock purchase plan		23		23
Ending balance, value at Jun. 30, 2019	$ 1	297,638	(294,142)	3,497
Ending balance, shares at Jun. 30, 2019	110,725,000
Net loss			(16,366)	(16,366)
Net settlement of options		13		13
Net settlement of options, shares	13,000
Share-based compensation		742		742
Employee stock purchase plan		57		57
Modification of existing warrants		1,564		1,564
Issuance of common stock in connection with Pro Farm acquisition.		20,299		20,299
Issuance of common stock in connection with Pro Farm acquisition, shares	12,666,000
Issuance of common stock in connection with call to exercise warrants		10,000		10,000
Issuance of common stock in connection with call to exercise warrants, shares	10,000,000
Issuance of new warrants in connection with call to exercise warrants		4,751		4,751
Ending balance, value at Sep. 30, 2019	$ 1	335,064	(310,508)	24,557
Ending balance, shares at Sep. 30, 2019	133,404,000
Beginning balance, value at Dec. 31, 2019	$ 1	344,206	(320,649)	23,558
Beginning balance, shares at Dec. 31, 2019	139,526,000
Net loss			(7,024)	(7,024)
Net settlement of options		12		12
Net settlement of options, shares	15,000
Share-based compensation		907		907
Employee stock purchase plan		84		84
Employee stock purchase plan, shares	0
Financing costs		(64)		(64)
Exercise of warrants, shares
Issuance of common stock in connection with exercise of warrants, shares
Issuance of common stock in connection with call to exercise warrants		6,000		6,000
Issuance of common stock in connection with call to exercise warrants, shares	6,000,000
Issuance of new warrants in connection with call to exercise warrants		1,391		1,391
Ending balance, value at Mar. 31, 2020	$ 1	352,536	(327,673)	24,864
Ending balance, shares at Mar. 31, 2020	145,541,000
Beginning balance, value at Dec. 31, 2019	$ 1	344,206	(320,649)	23,558
Beginning balance, shares at Dec. 31, 2019	139,526,000
Net loss				(15,957)
Ending balance, value at Sep. 30, 2020	$ 1	359,710	(336,606)	23,105
Ending balance, shares at Sep. 30, 2020	152,475,000
Beginning balance, value at Mar. 31, 2020	$ 1	352,536	(327,673)	24,864
Beginning balance, shares at Mar. 31, 2020	145,541,000
Net loss			(2,870)	(2,870)
Net settlement of options		2		2
Net settlement of options, shares	2,000
Share-based compensation		884		884
Employee stock purchase plan		45		45
Employee stock purchase plan, shares	159,000
Settlement of restricted stock units
Settlement of restricted stock units, shares	267,000
Exercise of warrants		2,544		2,544
Exercise of warrants, shares	3,393,000
Issuance of restricted stock units in lieu of bonus payments		632		632
Ending balance, value at Jun. 30, 2020	$ 1	356,643	(330,543)	26,101
Ending balance, shares at Jun. 30, 2020	149,362,000
Net loss			(6,063)	(6,063)
Net settlement of options		17		17
Net settlement of options, shares	19,000
Share-based compensation		964		964
Employee stock purchase plan		50		50
Settlement of restricted stock units
Settlement of restricted stock units, shares	380,000
Issuance of common stock in connection with exercise of warrants		2,036		2,036
Issuance of common stock in connection with exercise of warrants, shares	2,714,000
Ending balance, value at Sep. 30, 2020	$ 1	$ 359,710	$ (336,606)	$ 23,105
Ending balance, shares at Sep. 30, 2020	152,475,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (15,957)	$ (27,034)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,666	1,427
Gain on disposal of equipment	(9)	(9)
Right of use assets amortization	590	602
Share-based compensation	2,755	1,906
Non-cash interest expense	175	213
Loss on modification of warrants		1,564
Loss on issuance of new warrants	1,391	4,751
Change in fair value of contingent consideration	563
Net changes in operating assets and liabilities:
Accounts receivable	(902)	(4,043)
Inventories, Net	1,956	(84)
Prepaid Expenses and other assets	(529)	(904)
Accounts payable	(1,337)	(384)
Accrued and other liabilities	981	6,571
Lease Liability	(599)	(471)
Deferred revenue	(344)	(500)
Net cash used in operating activities	(8,600)	(16,395)
Cash flows from investing activities
Payment of contingent consideration in connection with previous asset purchase	(890)	(544)
Sale of property, plant, equipment	2
Business combination, net of cash acquired		(5,849)
Purchases of property, plant and equipment	(458)	(218)
Net cash used in investing activities	(1,346)	(6,611)
Cash flows from financing activities
Proceeds from secured borrowings	32,837	24,005
Reductions in secured borrowings	(30,461)	(21,123)
Net settlement of options
Financing costs	(64)
Exercise of stock options	31	55
Proceeds from employee stock purchase plan	179	80
Exercise of warrants	10,580	10,000
Repayment of debt	(437)	(333)
Net cash provided by financing activities	12,665	12,684
Net increase (decrease) in cash and cash equivalents and restricted cash	2,719	(10,322)
Cash and cash equivalents and restricted cash, beginning of period	7,812	19,781
Cash and cash equivalents and restricted cash, end of period	10,531	9,459
Supplemental disclosure of cash flow information
Cash paid for interest	884	794
Reclass of restricted stock units in lieu of cash bonus	632
Supplemental disclosure of non-cash investing and financing activities
Property, plant and equipment included in accounts payable and accrued liabilities	35	5
Fair value of non-cash consideration issued in acquisition transactions		$ 22,054

Summary of Business, Basis of P

Summary of Business, Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Business, Basis of Presentation	1. Summary of Business, Basis of Presentation Marrone Bio Innovations, Inc. (the “Company”), was incorporated under the laws of the State of Delaware on June 15, 2006 99% The accompanying condensed consolidated financial information as of September 30, 2020, and for the three and nine months ended September 30, 2020 and 2019, has been prepared by the Company, without audit, in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such SEC rules and regulations and accounting principles applicable for interim periods. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The information included in this Quarterly Report on Form 10-Q should be read in connection with the consolidated financial statements and accompanying notes included in the Company’s Annual Report filed on Form 10-K for the fiscal year ended December 31, 2019. In the opinion of management, the condensed consolidated financial statements as of September 30, 2020, and for the three and nine months ended September 30, 2020 and 2019, reflect all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations and cash flows. The results of operations for the three months and nine months ended September 30, 2020 are not necessarily indicative of the operating results for the full fiscal year or any future periods. The Company makes biological crop protection, plant health and plant nutrition products. The Company targets the major markets that use conventional chemical products, including certain agricultural markets where its biological products are used as alternatives for, or mixed with, conventional chemical products. The Company also targets new markets for which (i) there are no available conventional chemical products or (ii) the use of conventional chemical products may not be desirable or permissible to meet standards or regulations for organically produced crops or because the development of pest resistance has reduced the efficacy of conventional chemical products. The Company delivers EPA-approved and registered biological crop protection products and other biological products that address the global demand for effective, safe and environmentally responsible products. Going Concern, Liquidity, and Management Plans The accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue to operate under the assumption that there is substantial doubt about its ability to continue as a going concern, for 12 months after the issuance of these condensed consolidated financial statements. This assessment contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from the Company’s substantial doubt about its ability to continue as a going concern. The Company has a limited number of commercialized products and an operating history that includes periods of negative operating cash flows, which indicate substantial doubt exists related to the Company’s ability to continue as a going concern for the next 12 months from the date of issuance of these condensed consolidated financial statements. As of September 30, 2020, the Company had an accumulated deficit of $ 336,606 1,066 8,971 17,700 7,300 1,560 The Company believes that its existing cash and cash equivalents of $ 5,574 ,000 at November 6, 2020, together with expected revenues, expected future debt or equity financings and cost management will be sufficient to fund operations as currently planned through one year from the date of the issuance of these condensed consolidated financial statements. The Company anticipates securing additional sources of cash through equity and/or debt financings, collaborative or other funding arrangements with partners, or through other sources of financing, consistent with historic results. However, the Company cannot predict, with certainty, the outcome of its actions to grow revenues, to manage or reduce costs or to secure additional financing from outside sources on terms acceptable to the Company or at all. Further, the Company may continue to require additional sources of cash for general corporate purposes, which may include operating expenses, working capital to improve and promote its commercially available products, advance product candidates, expand international presence and commercialization, general capital expenditures and satisfaction of debt obligations and any potential negative economic impacts from the current COVID-19 pandemic on the Company’s operations. In April 2020, the Company entered into a Warrant Exchange Agreement (the “Warrant Exchange Agreement”) with a group of historical investors (the “Investors”). Pursuant to the Warrant Exchange Agreement, the Investors have exchanged certain previously issued and outstanding warrants to purchase an aggregate of up to 45,977,809 29,881,855 The New Warrants all have an exercise price of $ 0.75 per share, and expire in five tranches. As of September 30, 2020, a total of 6,106,646 Warrant Shares were exercised prior to the first and second tranche expiration dates of May 1, 2020 and September 15, 2020. The next warrant expiration dates are December 15, 2020, with respect to 13,027,512 Warrant Shares, March 15, 2021, with respect to 5,862,380 Warrant Shares, and December 15, 2021 with respect to 4,885,317 Warrant Shares. The total aggregate exercise price of all future New Warrants is approximately $ 17.8 million. There can be no assurance that the Investors will exercise the New Warrants prior to their respective expiration dates. (Refer to Note 7). If the Company breaches any of the covenants contained within any of its debt agreements or if the material adverse change clauses are triggered, the entire unpaid principal and interest balances would be due and payable upon demand. Without entering into a continuation of its current waiver, which expires November 30, 2021, entering into strategic agreements that include significant cash payments upfront, significantly increasing revenues from sales or raising additional capital through the issuance of equity, the Company expects it will exceed its maximum debt-to-worth requirement under the June 2014 Secured Promissory Note with Five Star Bank. Further, a violation of a covenant in one debt agreement will cause the Company to be in violation of certain covenants under each of its other debt agreements. Breach of covenants included in the Company’s debt agreements, which could result in the lenders demanding payment of the unpaid principal and interest balances, will have a material adverse effect upon the Company and would likely require the Company to seek to renegotiate these debt arrangements with the lenders. If such negotiations are unsuccessful, the Company may be required to seek protection from creditors through bankruptcy proceedings. The Company’s inability to maintain compliance with its debt covenants could have a negative impact on the Company’s financial condition and ability to continue as a going concern. The June 2014 Secured Promissory Note contains a material adverse change clause that could be invoked by the lender as a result of the uncertainty related to the Company’s ability to continue as a going concern. If the lender were to declare an event of default, the entire amount of borrowings related to all debt agreements at that time would have to be reclassified as current in the condensed consolidated financial statements. The lender has waived its right to deem recurring losses, liquidity, going concern, and financial condition a material adverse change through November 30, 2021. As a result of the waiver, none of the long-term portion of the Company’s outstanding debt has been reclassified to current in these condensed consolidated financial statements as of September 30, 2020. The Company participates in a heavily regulated and highly competitive crop protection industry and believes that adverse changes in any of the following areas could have a material effect on the Company’s future financial position, results of operations or cash flows: inability to obtain regulatory approvals, increased competition in the biological agricultural product market, market acceptance of the Company’s products, weather and other seasonal factors beyond the Company’s control, litigation or claims against the Company related to intellectual property, patents, products or governmental regulation, and the Company’s ability to support increased growth. The current COVID-19 pandemic, including prolonged domestic and global shelter in place orders, may further increase the risk of adverse changes in the above areas and the Company’s operating results. If the Company becomes unable to continue as a going concern, it may have to liquidate its assets, and stockholders may lose all or part of their investment in the Company’s common stock. Although the Company recognizes that it may need to raise additional funds in the future, there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will not be unfavorable. Any future equity financing may result in dilution to existing stockholders and any debt financing may include additional restrictive covenants. Any failure to obtain additional financing or to achieve the revenue growth necessary to fund the Company with cash flows from operations will have a material adverse effect upon the Company and will likely result in a substantial reduction in the scope of the Company’s operations and impact the Company’s ability to achieve its planned business objectives. The actions discussed above cannot be considered to mitigate the substantial doubt raised by its historical operating results and satisfying its estimated liquidity needs for 12 months from the issuance of these condensed consolidated financial statements.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company used significant estimates in accounting for assumptions and estimates associated with revenue recognition, including assumptions and estimates used in determining the timing and amount of revenue to recognize for those transactions with variable considerations, reserves for inventory obsolescence, fair value of stock-based compensation, and forecasted estimates and assumptions related to impairment analysis for long lived assets, intangibles, and goodwill and contingent considerations related to Pro Farm, assumptions and estimates associated with the fair value of warrants and in its going concern analysis. Concentrations of Credit Risks Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, accounts receivable and debt. The Company deposits its cash and cash equivalents with high credit quality domestic financial institutions with locations in the U.S. and internationally. Such deposits may exceed federal or national deposit insurance limits. The Company believes the financial risks associated with these financial instruments are minimal. The Company’s customer base is dispersed across many different geographic areas, and currently most customers are pest management distributors in the U.S. Generally, receivables are due up to 120 The Company’s principal sources of revenues are its Regalia, Grandevo, Venerate and LumiBio Kelta product lines. These four product lines accounted for 78% and 85% of the Company’s total revenues for the three months ended September 30, 2020 and 2019, respectively. These four product lines accounted for 85% and 91% of the Company’s total revenues for the nine months ended September 30, 2020 and 2019, respectively. Revenues generated from international customers were 26% 11% 26% 8% Customers to which 10% or more of the Company’s total revenues are attributable for the three months ended September 30, 2020 and 2019 consist of the following: Schedule of Significant Customer's Revenues and Account Receivable Percentage CUSTOMER A B C D E Three months ended September 30, 2020 25% 14% 12% 10% 6% 2019 26% 10% 0% 0% 13% Customers to which 10% or more of the Company’s total revenues are attributable for the nine months ended September 30, 2020 and 2019 consist of the following: CUSTOMER A B C D Nine months ended September 30, 2020 15% 15% 15% 8% 2019 26% 10% 0% 12% Customers to which 10% or more of the Company’s outstanding accounts receivable are attributable as of either September 30, 2020 or December 31, 2019, which may or may not correspond with any of the customers above, consist of the following: CUSTOMER A B C D September 30, 2020 32% 13% 10% 10% December 31, 2019 44% 0% 5% 4% Concentrations of Supplier Dependence The active ingredient in the Company’s Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company currently relies on one supplier for this plant. Such single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company’s manufacturing plant. The Company continues to rely on third parties to formulate Grandevo into spray-dried powders, for all of its production of Venerate, Majestene/Zelto, Stargus and Haven, and from time to time, third-party manufacturers for supplemental production capacity to meet excess seasonal demand and for packaging. The Company’s products have been produced in quantities, and on timelines, sufficient to meet commercial demand and for the Company to satisfy its delivery schedules. However, the Company’s dependence upon others for the production of a portion of its products, or for a portion of the manufacturing process, particularly for drying and for all of its production of Venerate, may adversely affect its ability to satisfy demand and meet delivery obligations, as well as to develop and commercialize new products, on a timely and competitive basis. The Company has not entered into any long-term manufacturing or supply agreements for any of its products, and it may need to enter into additional agreements for the commercial development, manufacturing and sale of its products. There can be no assurance that it can do so on favorable terms, if at all. Products produced by the Company’s Pro Farm subsidiary, including UBP and Foramin, are partially sourced by suppliers from a manufacturing plant in Russia, in which the Company owns a 12% Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows (in thousands): Schedule of Cash, Cash Equivalents and Restricted Cash SEPTEMBER 30, DECEMBER 31, Cash and cash equivalents $ 8,971 $ 6,252 Restricted cash 1,560 1,560 Total cash, cash equivalents and restricted cash $ 10,531 $ 7,812 Restricted Cash The Company’s restricted cash consists of cash that the Company is contractually obligated to maintain in accordance with the terms of its June 2014 Secured Promissory Note. See Note 6 for further discussion. Intangible Assets The Company evaluates intangible assets for impairment at least annually and more often whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value. The Company’s intangible assets include customer relationships, patents, trademarks, and in process research and development acquired in 2019 in connection with its asset acquisition of the Jet-Ag and Jet-Oxide product lines and the Company’s acquisition of Pro Farm. The Company has assessed for impairment in contemplation of the COVID-19 pandemic and has not recorded an impairment of intangible assets as of September 30, 2020. Long-Lived Assets Impairment losses related to long-lived assets are recognized in the event the net carrying value of such assets is not recoverable and exceeds fair value. The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group). If the carrying amount of a long-lived asset (asset group) is considered not recoverable, the impairment loss is measured as the amount by which the carrying value of the asset or asset group exceeds its estimated fair value. The Company has assessed for impairment in contemplation of the COVID-19 pandemic and has not recorded impairment of long-lived assets as of September 30, 2020. Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Goodwill is reviewed for impairment on an annual basis as of the first day of the Company’s fiscal fourth quarter or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. The Company has assessed for impairment in contemplation of the COVID-19 pandemic and has not recorded impairment in goodwill as of September 30, 2020. The Company is currently in the process of completing its annual impairment assessment, which may or may not result in an impairment charge. Fair Value Accounting Standards Codification (“ASC”) 820, Fair Value Measurements (“ASC 820”), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three-tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability. Deferred Revenue When the Company receives consideration, or such consideration is unconditionally due, from a customer prior to transferring control of goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability. The Company recognizes deferred revenue as net sales after the Company has transferred control of the goods or services to the customer and all revenue recognition criteria are met. The Company’s deferred revenue is broken out as follows (in thousands): Schedule of Deferred Revenue SEPTEMBER 30, 2020 DECEMBER 31, 2019 Product revenues $ 330 $ 299 Financing costs 599 609 License revenues 1,300 1,505 Deferred revenue 2,229 2,413 Less current portion (541 ) (427 ) Deferred revenue, less current portion $ 1,688 $ 1,986 Research, Development and Patent Expenses Research and development expenses include payroll-related expenses, field trial costs, toxicology costs, regulatory costs, consulting costs and lab costs. Patent expenses include legal costs relating to the patents and patent filing costs. These costs are expensed to operations as incurred. For the three months ended September 30, 2020 and 2019, research and development expenses totaled $ 2,860 ,000 and $3,473 ,000, respectively, and patent expenses totaled $252,000 and $ 287,000 , respectively. For the nine months ended September 30, 2020 and 2019, research and development expenses totaled $ 7,816,000 and $ 9,490,000 , respectively, and patent expenses totaled $ 842,000 and $ 846,000 , respectively. The Company’s receipt of PPP funds did not have any impact on research, development and patent expenses for the three months ended September 30, 2020. The Company’s receipt of PPP funds for nine months ended September 30, 2020, reduced expenses for research, development and patent expenses by $ 702,000 . Shipping and Handling Costs Amounts billed for shipping and handling are included as a component of product revenues. Related costs for shipping and handling have been included as a component of cost of product revenues. Shipping and handling costs for the three months ended September 30, 2020 and 2019 were $ 435,000 281,000 1,153,000 998,000 Advertising The Company expenses advertising costs as incurred and has included these expenses as a component of selling, general and administrative costs. Advertising costs for the three months ended September 30, 2020 and 2019 were $ 186,000 173,000 476,000 548,000 Depreciation and Amortization The Company depreciates and amortizes its capitalized property, plant, and equipment and intangible assets over the useful life of each asset utilizing a straight-line method of expensing. All depreciation and amortization expenses are included in the “Selling, general, and administrative” caption in the condensed consolidated statement of operations. For the three months ended September 30, 2020 and 2019, the total amount of depreciation expense was $ 298,000 359,000 903,000 1,262,000 For the three months ended September 30, 2020 and 2019, the total amount of amortization expense was $ 587,000 165,000 1,763,000 165,000 Segment Information The Company is organized as a single One Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. The calculation of basic and diluted net loss per share is the same for all periods presented as the effect of certain potential common stock equivalents, which consist of stock options and warrants to purchase common stock and restricted stock units, and contingent shares to be issued in the future are anti-dilutive due to the Company’s net loss position. Anti-dilutive common stock equivalents are excluded from diluted net loss per share. The following table sets forth the potential shares of common stock as of the end of each period presented that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share SEPTEMBER 30, 2020 2019 Stock options outstanding 13,709 12,056 Warrants to purchase common stock 30,444 52,647 Restricted stock units outstanding 4,475 1,918 Common shares to be issued in lieu of agent fees 498 498 Employee stock purchase plan 59 65 Maximum contingent consideration shares to be issued 5,972 5,972 55,157 73,156

Inventory, net

Inventory, net	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventory, net	3. Inventory, net Inventories, net consist of the following (in thousands): Schedule of Inventory SEPTEMBER 30, DECEMBER 31, 2020 2019 Raw materials $ 2,162 $ 1,610 Work in progress 896 783 Finished goods 3,135 5,756 Inventories, net $ 6,193 $ 8,149 As of September 30, 2020 and December 31, 2019, the Company had $ 353,000 248,000 217,000 109,000 600,000 317,000 1,230,000 643,000

Right-Of-Use of Assets and Leas

Right-Of-Use of Assets and Lease Liability	9 Months Ended
	Sep. 30, 2020
Right-of-use Of Assets And Lease Liability
Right-Of-Use of Assets and Lease Liability	4. Right-Of-Use of Assets and Lease Liability The components of lease expense were as follows for each of the comparative three and nine months ended September 30, 2020 and 2019 (in thousands): Schedule of Components of Lease Expense THREE MONTHS ENDED THREE MONTHS ENDED SEPTEMBER 30, 2020 SEPTEMBER 30, 2019 Operating lease cost $ 290 $ 287 Short-term lease cost 38 20 Sublease income (7 ) (25 ) Total operating lease costs $ 321 $ 282 NINE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, 2020 SEPTEMBER 30, 2019 Operating lease cost $ 864 $ 874 Short-term lease cost 109 53 Sublease income (27 ) (73 ) Total operating lease costs $ 946 $ 854 Maturities of lease liabilities for each future calendar year as of September 30, 2020 are as follows (in thousands): Schedule of Maturities of Lease Liabilities OPERATING LEASES 2020, remaining 3 months $ 301 2021 1,231 2022 1,267 2023 1,293 2024 and beyond 867 Total lease payments 4,959 Less: imputed interest 675 Total lease obligation 4,284 Less lease obligation, current portion 981 Lease obligation, non-current portion $ 3,303

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued Liabilities	5. Accrued Liabilities Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities SEPTEMBER 30, DECEMBER 31, 2020 2019 Accrued compensation $ 3,406 $ 2,730 Accrued warranty costs 487 327 Accrued customer incentives 4,172 5,102 Accrued liabilities, acquisition related 2,126 1,722 Accrued liabilities, other 2,910 2,586 Accrued liabilities, total $ 13,101 $ 12,467 Product Warranty The Company warrants the specifications of its products through implied product warranties and has extended product warranties to qualifying customers on a contractual basis. The Company estimates the costs that may be incurred during the warranty period and records a liability in the amount of such costs at the time product is shipped. The Company’s estimate is based on historical experience and estimates of future warranty costs as a result of increased usage of the Company’s products. During the three months ended September 30, 2020 and 2019, the Company recognized $ 19,000 and $ 75,500 , respectively in warranty expense associated with product shipments for the period. This expense was reduced by $ 29,000 for the three months ended September 30, 2019 as a result of the historical usage of warrant reserves being lower than previously estimated and during the three months ended September 30, 2019 the Company recognized $ 29,000 in warranty claims. For the three months ended September 30, 2020, the Company there was no were no 241,000 and $ 245,000 , respectively in warranty expense associated with product shipments for the period. This expense was reduced by $ 81,000 and $ 173,000 for the nine months ended September 30, 2020 and 2019, respectively, for the reason set forth above. The Company did not settle any warranty claims for the nine months ended September 30, 2020. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amount, as necessary. Changes in the Company’s accrued warranty costs during the period are as follows (in thousands): Schedule of Changes in Accrued Warranty Costs Balance at December 31, 2019 $ 327 Warranties issued (released) during the period 160 Settlements made during the period - Balance at September 30, 2020 $ 487 Contingent Consideration As of September 30, 2020, the contingent consideration in connection with the Company’s acquisition of Pro Farm was recorded at its fair value. The following table provides a reconciliation of the activity for the contingent consideration measured between the most recent reporting period and as of the balance sheet date based on the fair value using significant inputs including the unobservable inputs (Level 3) (in thousands): Schedule of Derivative Liability Measured at Fair Value Using Unobservable Inputs CONTINGENT CONSIDERATION Fair value at December 31, 2019 $ 1,737 Change in estimated fair value recorded of contingent consideration 563 Fair value at September 30, 2020 $ 2,300 The change in fair value for the reporting period was driven by the result of the unobservable fair value model, a Monte Carlo simulation in a risk-neutral framework assuming Geometric Browning Motion. The most significant input to the model was the estimated results of the Pro Farm subsidiary for the periods specified in the share purchase agreement of 2020 – 2023. The following represents other inputs used in determining the fair value of the contingent consideration liability: Schedule of Fair value of Contingent Consideration Liability SEPTEMBER 30, DECEMBER 31, 2020 2019 Discount rate 13.9% 15.2% Volatility 49.6% 33.6% Credit spread 12.2% 10.8% Risk-free rate 0.19% 1.66% Discount Rate. Estimated Volatility Factor. Credit Spread. Interest Rate. The change in the fair value estimate is recognized in the Company’s condensed consolidated statement of operations in Other Income (expense) under caption Change in fair value of contingent consideration. The contingent consideration will be determined at each reporting period and will be settled with the issuance of the Company’s common shares. As of September 30, 2020, the Company recorded $ 1,006,000 1,294,000

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	6. Debt Debt, including debt due to related parties, consists of the following (in thousands): Schedule of Debt Including Debt to Related Parties SEPTEMBER 30, DECEMBER 31, 2020 2019 Secured promissory notes (“October 2012 and April 2013 Secured Promissory Notes”) bearing interest at 8.00% December 31, 2022 $ 3,425 $ 3,425 Secured promissory note (“June 2014 Secured Promissory Note”) bearing interest at prime plus 2% 5.25% payable monthly through June 2036 170 185 8,187 8,404 Secured revolving borrowing (“LSQ Financing”) bearing interest at ( 12.80% November 2020 6,004 3,629 Senior secured promissory notes due to related parties (“August 2015 Senior Secured Promissory Notes”) bearing interest at 8% December 31, 2022 7,300 7,300 Research loan facility (“2018 Research Facility”) bearing interest at 1.00 25 ility beginning on the fourth anniversary of the loan ( September 2022 ), net of imputed interest as of September 30, 2020 of $ 9 . 84 81 Financial institution facility (“2018 Bank Facility”) bearing interest at Euribor plus 2.40% per annum, interest payable monthly and principal payable at maturity ( May 1, 2020 ), 60% guaranteed by Export Credit Agency of Finland for a fee of 2.49% . - 207 Debt, including debt due to related parties 25,000 23,046 Less debt due to related parties, non-current (7,300 ) (7,300 ) Less current portion (6,333 ) (3,899 ) Debt, non-current $ 11,367 $ 11,847 As of September 30, 2020, aggregate contractual future principal payments on the Company’s debt, including debt due to related parties for each calendar year, are due as follows (in thousands): Schedule of Contractual Future Principal Payments Period ended September 30, 2020 Debt Debt to Related Party 2020 $ 6,089 $ - 2021 353 - 2022 2,822 5,000 2023 416 - 2024 436 - Thereafter 6,788 - Total future principal payments 16,904 5,000 Interest payments included in debt balance (1) 975 2,300 $ 17,879 $ 7,300 (1) Due to the debt extinguishment requirements, the Company has included both accrued interest and future interest in the debt balance for certain outstanding debt. October 2012 and April 2013 Secured Promissory Notes As of September 30, 2020, there have been no changes to the previously reported total principal amount outstanding under the October 2012 and April 2013 Secured Promissory Note, which continues to be $ 2,450,000 3,425,000 975,000 533,000 337,000 The October 2012 and April 2013 Secured Promissory Notes contain representations and warranties by the Company and the lender, certain indemnification provisions in favor of the lenders, customary covenants (including limitations on other debt, liens, acquisitions, investments and dividends), events of default (including payment defaults, breaches of covenants, a material impairment in the lender’s security interest or in the collateral, and events relating to bankruptcy or insolvency), and also restrictive covenants. As of September 30, 2020, the Company is in compliance with all related covenants, or has received an appropriate waiver of these covenants. June 2014 Secured Promissory Note In June 2014, the Company borrowed $ 10,000,000 5.25% 2.00% 1,560,000 Under this note the Company is required to maintain a current ratio of not less than 1.25-to-1.0, a debt-to-worth ratio of no greater than 4.0-to-1.0 and a loan-to-value ratio of no greater than 70% as determined by Five Star Bank. The following table reflects the activity under this note (in thousands): Schedule of Debt Activity 2020 2019 Principal balance, net at December 31, preceding year $ 8,404 $ 8,639 Principal payments (624 ) (545 ) Interest 392 328 Debt discount amortization 15 10 Principal balance, net at September 30, $ 8,187 $ 8,432 LSQ Financing In January 2020, the Company entered into a Second Amendment to the Company’s Invoice Purchase Agreement with LSQ. The amendment, among other things, (i) increased the amount of eligible customer invoices which LSQ may elect to purchase from the Company to up to $ 20,000,000 7,000,000 90% 85% 70% 60% In addition to the Amendment, the Company simultaneously entered into an Amended Inventory Financing Addendum (the “Addendum”) with LSQ. The Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company’s unpaid finished goods inventory; (ii) 65% of the appraised value of the Company’s inventory performed on or on behalf of LSQ; or (iii) $3,000,000. Funds advance under the Addendum are subject to a monthly inventory management fee of 0.5% on the average monthly inventory funds available and a daily interest rate of 0.025%. The agreement contains representations and warranties by the Company and LSQ, certain indemnification provisions in favor of LSQ and customary covenants (including limitations on other debt, liens, acquisitions, investments and dividends), and events of default (including payment defaults, breaches of covenants, a material impairment in LSQ’s security interest or in the collateral, and events relating to bankruptcy or insolvency). The Company is in compliance with all terms of the agreement. For the three months ended September 30, 2020 and 2019, the Company recorded interest expense of approximately $ 188,000 121,000 454,000 303,000 6,004,000

Warrants

Warrants	9 Months Ended
	Sep. 30, 2020
Warrants
Warrants	7. Warrants On August 6, 2019, the Company entered into a warrant amendment and plan of reorganization agreement (“Warrant Reorganization Agreement”) with certain holders of the February 2018 Warrants. Pursuant to the Warrant Reorganization Agreement, the Company agreed to extend the expiration date under the February 2018 Warrants held by such holders from December 2020 to December 2021 1.00 36,600,000 In August and through December 2019, the Company requested under the Warrant Reorganization Agreement, the exercise of 16,000,000 6,000,000 6,000,000 6,000,000 1,391,000 Schedule of Fair Value Warrant Assumptions Call Option Exercise WARRANTS 2020 Expected life (years) 3.01 3.04 Estimated volatility factor 52.9 53.1 % Risk-free interest rate 1.58 1.66 % Expected dividend yield — Expected Life. Estimated Volatility Factor. Risk-Free Interest Rate. Expected Dividend Yield. On April 29, 2020, the Company entered into a warrant exchange agreement (“Warrant Exchange Agreement”) with certain holders of warrants under the August 2015 Senior Secured Promissory Notes, the Securities Purchase Agreement and the Amendment and Plan of Reorganization agreements. Pursuant to the Warrant Exchange Agreement, the Company agreed to exchange an aggregate of 45,977,809 29,881,855 The April 2020 Warrants have terms expiring (i) for a total of 3,392,581 2,714,065 13,027,512 5,862,380 4,885,317 0.75 The Company has accounted for the Warrant Exchange Agreement as a modification under Accounting Standards Codification (“ASC”) 718, Compensation – Stock Based Compensation Schedule of Fair Value Warrant Assumptions Exchanged Warrants EXCHANGED WARRANTS APRIL 2020 WARRANTS Expected life (years) 0.68 3.31 0.38 1.63 Estimated volatility factor 43.0 52.2 % 38.1 46.3 % Risk-free interest rate 0.14 0.26 % 0.10 0.19 % Expected dividend yield — — Expected Life. Estimated Volatility Factor. Risk-Free Interest Rate. Expected Dividend Yield. The following table summarizes information about the Company’s common stock warrants outstanding activity through September 30, 2020 (in thousands, except exercise price data): Summary of Information About Common Stock Warrants Outstanding NUMBER OF NINE MONTHS NINE MONTHS ENDED NUMBER NINE MONTHS NUMBER OF SHARES ENDED OF ENDED SHARES SUBJECT TO NUMBER OF WARRANTS OR NUMBER OF SUBJECT TO ISSUE EXPIRATION WARRANTS WARRANTS SHARES WARRANTS WARRANTS DATE DATE EXERCISE ISSUED EXERCISED ISSUED EXCHANGED ISSUED DESCRIPTION MM/YY MM/YY PRICE 12/31/2019 9/30/2020 9/30/2020 9/30/2020 9/30/2020 June 2013 Warrants 06/13 06/23 (1) $ 8.40 27 - - - 27 August 2015 Warrants 08/15 08/23 $ 1.91 4,000 - - (4,000 ) - November 2016 Warrants 11/16 11/26 $ 2.38 125 - - - 125 November 2017 Warrants 06/17 06/27 $ 1.10 80 - - - 80 February 2018 Warrants 1 02/18 12/20 $ 1.00 6,750 - - (1,378 ) 5,372 February 2018 Warrants 2 02/18 12/20 $ 1.25 5,065 - - (4,000 ) 1,065 August 2019 Warrant 09/19 12/21 $ 1.00 20,600 (6,000 ) - (14,600 ) - August 2019 Warrant (Call Option) Various after 08/19 01/23 $ 1.75 16,000 - 6,000 (22,000 ) - April 2020 Warrants, Tranche 1 04/20 05/20 $ 0.75 - (3,393 ) 3,393 - - April 2020 Warrants, Tranche 2 04/20 09/20 $ 0.75 - (2,714 ) 2,714 - - April 2020 Warrants, Tranche 3 04/20 12/20 $ 0.75 - - 13,028 - 13,028 April 2020 Warrants, Tranche 4 04/20 03/21 $ 0.75 - - 5,862 - 5,862 April 2020 Warrants, Tranche 5 04/20 12/21 $ 0.75 - - 4,885 - 4,885 52,647 (12,107 ) 35,882 (45,978 ) 30,444 The weighted average remaining contractual life and exercise price for these warrants is 0.47 0.83 (1) The June 2013 Warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company); or (iii) a sale of all or substantially all of the assets of the Company unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise), hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.

Share-Based Plans

Share-Based Plans	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Plans	8. Share-Based Plans Under the Company’s Employee Stock Purchase Plan (the “ESPP”), employees may purchase Company stock through payroll deductions over each six-month period beginning on each June 1 and December 1 (the “Offer Period”). The purchase price of the shares will be 85% 18,000 55,000 13,000 18,000 As of September 30, 2020, there were options to purchase 13,709,000 4,475,000 288,000 For the three months ended September 30, 2020 and 2019, the Company recognized share-based compensation of $ 946,000 742,000 2,699,000 1,888,000 In August 2020, in connection with the retirement of its chief executive officer, the Company granted 2,450,000 1.16 899,000 Schedule of Assumptions Utilized in Option Pricing Model AUGUST 3, 2020 Expected life (years) 2.14 6.08 Estimated volatility factor 58.8 % Risk-free interest rate 0.28 % Expected dividend yield — Expected Life. Share-Based Payment Simplified Method for Plain Vanilla Share Options Estimated Volatility Factor. Risk-Free Interest Rate. Expected Dividend Yield During the three months ended September 30, 2020 and 2019, the Company granted options to purchase 2,612,000 5,363,000 1.16 1.43 19,000 13,000 0.90 1.16 The following table summarizes the activity of stock options from December 31, 2019 to September 30, 2020 (in thousands, except weighted average exercise price): Summary of Stock Options Activity WEIGHTED- AVERAGE EXERCISE OPTIONS PRICE Balance at December 31, 2019 11,821 $ 2.53 Options granted 2,612 1.16 Options exercised (36 ) 0.87 Options cancelled (688 ) 1.90 Balance at September 30, 2020 13,709 2.30 In May 2020, the Company granted to certain executives restricted stock units in lieu of ten percent of their annual base salaries for the fiscal year ending December 31, 2020. The total number of restricted stock units granted to these executives was 225,000 0.71 In May 2020 the Company also the granted restricted stock units to certain executives and employees in lieu of cash bonuses for performance related to the fiscal year ended December 31, 2019. The total number of restricted stock units granted to these employees was 890,000 0.71 632,000 In August 2020, in connection with the Company’s separation and consulting arrangement with its former chief executive officer, the Company granted 1,250,000 The following table summarizes the activity of restricted stock units from December 31, 2019 to September 30, 2020 (in thousands, except weighted average grant date fair value): Summary of Restricted Stock Units Activity WEIGHTED- RESTRICTED AVERAGE STOCK EXERCISE UNITS PRICE Outstanding at December 31, 2019 2,405 $ 1.40 Granted 2,742 0.96 Exercised (647 ) 1.23 Forfeited (25 ) 1.37 Outstanding at September 30, 2020 4,475 $ 1.14 The following table summarizes the activity of non-vested restricted stock units from December 31, 2019 to September 30, 2020 (in thousands, except weighted average grant date fair value): Summary of Non-vested Restricted Stock Units Activity WEIGHTED AVERAGE GRANT SHARES DATE FAIR OUTSTANDING VALUE Nonvested at December 31, 2019 711 $ 1.45 Granted 2,742 $ 0.96 Vested (1,951 ) $ 1.00 Forfeited (25 ) $ 1.37 Nonvested at September 30, 2020 1,477 $ 1.15

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions Warrant Exchange Ospraie, Ivy Science & Technology Fund (“IS&T”), Ivy VIP Science & Technology (“Ivy VIP” and, together with IS&T, the “Waddell Investors”, and Ardsley, are beneficial owners of the Company’s securities, holding 41.7% , 17.9% , and 11.1% , respectively, of the Company’s total outstanding common stock as of September 30, 2020. In April 2020, in connection with the Company’s execution of the Warrant Exchange Agreement (See Note 7) various warrants held by Ospraie, the Waddell Investors, and Ardsley aggregating a total of 30,666,667 , 8,000,000 , and 5,222,333 shares, respectively, were exchanged for a total of 21,736,081 , 3,397,157 , and 3,780,185 , April 2020 Warrants, respectively. Warrant Exercises In March 2020, 6,000,000 6,000,000 6,000,000 5,027,325 874,314 In May and September 2020, 3,392,581 2,714,065 4,441,979 694,242 722,517 August 2015 Senior Secured Promissory Notes As of September 30, 2020, there have been no changes to the previously reported total principal amount outstanding under the August 2015 Senior Secured Promissory Notes, which continues to be $ 5,000,000 . Due to the historical accounting for the promissory note the amount recorded on the condensed consolidated balance sheet of $ 7,300,000 includes $ 2,300,000 in accrued interest, of which as of September 30, 2020 and 2019, a total of $ 1,399,000 and $ 988,000 , respectively, had been incurred. The August 2015 Senior Secured Promissory Notes provide for various events of default, including, among others, default in payment of principal or interest, breach of any representation or warranty by the Company or any subsidiary under any agreement or document delivered in connection with the notes, a continued breach of any other condition or obligation under any loan document, certain bankruptcy, liquidation, reorganization or change of control events, the acquisition by any person or persons acting as group, other than the lenders, of beneficial ownership of 40%

Other Matters

Other Matters	9 Months Ended
	Sep. 30, 2020
Other Matters
Other Matters	10. Other Matters Paycheck Protection Program In April 2020, the Company entered into an unsecured note (the “Note”) in the amount of $ 1,723,000 under the PPP. Accounting for Government Grants For the nine months ended September 30, 2020, the Company recognized as reduction to the expense categories specified under the PPP $ 702,000 and $ 695,000 , respectively, in Research, development and patents and Selling, general and administrative in the condensed consolidated statement of operations. No amounts were recognized as reduction to Research, development and patents and Selling, general and administrative in the condensed consolidated statement of operations for the three months ended September 30, 2020. The remaining amount of total PPP funds received of $ 326,000 109,000 was amortized from Inventories, net, offsetting cost of product revenues in the consolidated statement of operations based on the Company’s normal recognition policy for similar items. A total of $ 217,000 will be recognized in future periods into cost of product revenues in the condensed consolidated statement of operations. Chief Financial Officer Retirement On September 21, 2020, James Boyd announced his intention to retire as the Company’s Chief Financial Officer (“CFO”) and President and an employee of the Company. In connection with his retirement, Mr. Boyd entered into the Separation Agreement on September 21, 2020 (the “Separation Agreement”). The Separation Agreement provides that Mr. Boyd’s retirement as an employee and officer of the Company will become effective immediately prior to the date on which a new CFO is retained. In addition to being entitled to any unpaid salary through his retirement date and continued COBRA coverage, in consideration of his execution of certain releases, Mr. Boyd will be entitled under the Separation Agreement to (i) salary continuation (payable at the annual rate of $ 330,000 In connection and in conjunction with Mr. Boyd’s retirement, he also entered into a consulting services agreement with the Company on September 21, 2020 (the “Consulting Agreement”). Pursuant to the Consulting Agreement, Mr. Boyd will serve as a consultant to the Company for a period of one year following the date of his retirement unless terminated earlier as discussed below or extended by mutual agreement of the Company and Mr. Boyd, to help the Company create and develop an entity dedicated to the eradication of invasive species with the terms of such services and related deliverables detailed in the Consulting Agreement. As consideration for his service as a consultant, Mr. Boyd will receive a one-time award of 200,000

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events The Company held its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) on October 29, 2020. The Company’s stockholders considered and voted on the following proposals at the 2020 Annual Meeting: (i) The Company’s stockholders elected Pamela G. Marrone, Ph.D., Robert A. Woods, and Yogesh Mago to serve as a Class I directors for a three-year term, ending at the time of the 2023 Annual Meeting of Stockholders (or until a successor is duly elected and qualified) pursuant to the Company’s Bylaws and the applicable laws of the State of Delaware. (ii) The Company’s stockholders ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. (iii) The Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to permit the Company’s board of directors to effect a reverse stock split of the Company’s outstanding common stock at a ratio of not less than one-for-five (1:5) and not more than one-for-fifteen (1:15), which exact ratio will be selected at the discretion of the board of directors, and provided that the board of directors may abandon the reverse stock split in its sole discretion. (iv) The Company’s stockholders approved the anti-dilution provisions in certain warrants in accordance with Nasdaq Listing Rule 5635(d). (v) The Company’s stockholders did not approve the stockholder proposal that the Company’s board of directors take each step necessary so that each voting requirement in the Company’s Certificate of Incorporation and Bylaws that calls for a greater than simple majority vote be eliminated, and replaced by a requirement for a majority of the votes cast for and against applicable proposals, or a simple majority in compliance with applicable laws, to take effect within four years. The full results of the Company’s 2020 Annual Meeting of Stockholders are included in the Company’s Form 8-K filed with the Securities and Exchange Commission on November 2, 2020. In addition, on November 2, 2020, following the 2020 Annual Meeting, the Company’s board of directors approved an increase in the size of the board of directors to eight people, with the one additional vacancy being in Class III, effective immediately. The board of directors appointed Lara L. Lee to fill the vacancy as a Class III director of the Company, with Ms. Lee’s term to expire as of the Company’s 2022 Annual Meeting of Stockholders. Ms. Lee will serve on the Audit Committee and Compensation Committee of the board of directors. The Company has evaluated its subsequent events from September 30, 2020 through the date these condensed consolidated financial statements were issued, and has determined that there are no additional subsequent events required to be disclosed.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company used significant estimates in accounting for assumptions and estimates associated with revenue recognition, including assumptions and estimates used in determining the timing and amount of revenue to recognize for those transactions with variable considerations, reserves for inventory obsolescence, fair value of stock-based compensation, and forecasted estimates and assumptions related to impairment analysis for long lived assets, intangibles, and goodwill and contingent considerations related to Pro Farm, assumptions and estimates associated with the fair value of warrants and in its going concern analysis.
Concentrations of Credit Risks	Concentrations of Credit Risks Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, accounts receivable and debt. The Company deposits its cash and cash equivalents with high credit quality domestic financial institutions with locations in the U.S. and internationally. Such deposits may exceed federal or national deposit insurance limits. The Company believes the financial risks associated with these financial instruments are minimal. The Company’s customer base is dispersed across many different geographic areas, and currently most customers are pest management distributors in the U.S. Generally, receivables are due up to 120 The Company’s principal sources of revenues are its Regalia, Grandevo, Venerate and LumiBio Kelta product lines. These four product lines accounted for 78% and 85% of the Company’s total revenues for the three months ended September 30, 2020 and 2019, respectively. These four product lines accounted for 85% and 91% of the Company’s total revenues for the nine months ended September 30, 2020 and 2019, respectively. Revenues generated from international customers were 26% 11% 26% 8% Customers to which 10% or more of the Company’s total revenues are attributable for the three months ended September 30, 2020 and 2019 consist of the following: Schedule of Significant Customer's Revenues and Account Receivable Percentage CUSTOMER A B C D E Three months ended September 30, 2020 25% 14% 12% 10% 6% 2019 26% 10% 0% 0% 13% Customers to which 10% or more of the Company’s total revenues are attributable for the nine months ended September 30, 2020 and 2019 consist of the following: CUSTOMER A B C D Nine months ended September 30, 2020 15% 15% 15% 8% 2019 26% 10% 0% 12% Customers to which 10% or more of the Company’s outstanding accounts receivable are attributable as of either September 30, 2020 or December 31, 2019, which may or may not correspond with any of the customers above, consist of the following: CUSTOMER A B C D September 30, 2020 32% 13% 10% 10% December 31, 2019 44% 0% 5% 4%
Concentrations of Supplier Dependence	Concentrations of Supplier Dependence The active ingredient in the Company’s Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company currently relies on one supplier for this plant. Such single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company’s manufacturing plant. The Company continues to rely on third parties to formulate Grandevo into spray-dried powders, for all of its production of Venerate, Majestene/Zelto, Stargus and Haven, and from time to time, third-party manufacturers for supplemental production capacity to meet excess seasonal demand and for packaging. The Company’s products have been produced in quantities, and on timelines, sufficient to meet commercial demand and for the Company to satisfy its delivery schedules. However, the Company’s dependence upon others for the production of a portion of its products, or for a portion of the manufacturing process, particularly for drying and for all of its production of Venerate, may adversely affect its ability to satisfy demand and meet delivery obligations, as well as to develop and commercialize new products, on a timely and competitive basis. The Company has not entered into any long-term manufacturing or supply agreements for any of its products, and it may need to enter into additional agreements for the commercial development, manufacturing and sale of its products. There can be no assurance that it can do so on favorable terms, if at all. Products produced by the Company’s Pro Farm subsidiary, including UBP and Foramin, are partially sourced by suppliers from a manufacturing plant in Russia, in which the Company owns a 12%
Cash and Cash Equivalents	Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows (in thousands): Schedule of Cash, Cash Equivalents and Restricted Cash SEPTEMBER 30, DECEMBER 31, Cash and cash equivalents $ 8,971 $ 6,252 Restricted cash 1,560 1,560 Total cash, cash equivalents and restricted cash $ 10,531 $ 7,812
Restricted Cash	Restricted Cash The Company’s restricted cash consists of cash that the Company is contractually obligated to maintain in accordance with the terms of its June 2014 Secured Promissory Note. See Note 6 for further discussion.
Intangible Assets	Intangible Assets The Company evaluates intangible assets for impairment at least annually and more often whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value. The Company’s intangible assets include customer relationships, patents, trademarks, and in process research and development acquired in 2019 in connection with its asset acquisition of the Jet-Ag and Jet-Oxide product lines and the Company’s acquisition of Pro Farm. The Company has assessed for impairment in contemplation of the COVID-19 pandemic and has not recorded an impairment of intangible assets as of September 30, 2020.
Long-Lived Assets	Long-Lived Assets Impairment losses related to long-lived assets are recognized in the event the net carrying value of such assets is not recoverable and exceeds fair value. The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group). If the carrying amount of a long-lived asset (asset group) is considered not recoverable, the impairment loss is measured as the amount by which the carrying value of the asset or asset group exceeds its estimated fair value. The Company has assessed for impairment in contemplation of the COVID-19 pandemic and has not recorded impairment of long-lived assets as of September 30, 2020.
Goodwill	Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Goodwill is reviewed for impairment on an annual basis as of the first day of the Company’s fiscal fourth quarter or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. The Company has assessed for impairment in contemplation of the COVID-19 pandemic and has not recorded impairment in goodwill as of September 30, 2020. The Company is currently in the process of completing its annual impairment assessment, which may or may not result in an impairment charge.
Fair Value	Fair Value Accounting Standards Codification (“ASC”) 820, Fair Value Measurements (“ASC 820”), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three-tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
Deferred Revenue	Deferred Revenue When the Company receives consideration, or such consideration is unconditionally due, from a customer prior to transferring control of goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability. The Company recognizes deferred revenue as net sales after the Company has transferred control of the goods or services to the customer and all revenue recognition criteria are met. The Company’s deferred revenue is broken out as follows (in thousands): Schedule of Deferred Revenue SEPTEMBER 30, 2020 DECEMBER 31, 2019 Product revenues $ 330 $ 299 Financing costs 599 609 License revenues 1,300 1,505 Deferred revenue 2,229 2,413 Less current portion (541 ) (427 ) Deferred revenue, less current portion $ 1,688 $ 1,986
Research, Development and Patent Expenses	Research, Development and Patent Expenses Research and development expenses include payroll-related expenses, field trial costs, toxicology costs, regulatory costs, consulting costs and lab costs. Patent expenses include legal costs relating to the patents and patent filing costs. These costs are expensed to operations as incurred. For the three months ended September 30, 2020 and 2019, research and development expenses totaled $ 2,860 ,000 and $3,473 ,000, respectively, and patent expenses totaled $252,000 and $ 287,000 , respectively. For the nine months ended September 30, 2020 and 2019, research and development expenses totaled $ 7,816,000 and $ 9,490,000 , respectively, and patent expenses totaled $ 842,000 and $ 846,000 , respectively. The Company’s receipt of PPP funds did not have any impact on research, development and patent expenses for the three months ended September 30, 2020. The Company’s receipt of PPP funds for nine months ended September 30, 2020, reduced expenses for research, development and patent expenses by $ 702,000 .
Shipping and Handling Costs	Shipping and Handling Costs Amounts billed for shipping and handling are included as a component of product revenues. Related costs for shipping and handling have been included as a component of cost of product revenues. Shipping and handling costs for the three months ended September 30, 2020 and 2019 were $ 435,000 281,000 1,153,000 998,000
Advertising	Advertising The Company expenses advertising costs as incurred and has included these expenses as a component of selling, general and administrative costs. Advertising costs for the three months ended September 30, 2020 and 2019 were $ 186,000 173,000 476,000 548,000
Depreciation and Amortization	Depreciation and Amortization The Company depreciates and amortizes its capitalized property, plant, and equipment and intangible assets over the useful life of each asset utilizing a straight-line method of expensing. All depreciation and amortization expenses are included in the “Selling, general, and administrative” caption in the condensed consolidated statement of operations. For the three months ended September 30, 2020 and 2019, the total amount of depreciation expense was $ 298,000 359,000 903,000 1,262,000 For the three months ended September 30, 2020 and 2019, the total amount of amortization expense was $ 587,000 165,000 1,763,000 165,000
Segment Information	Segment Information The Company is organized as a single One
Net Loss Per Share	Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. The calculation of basic and diluted net loss per share is the same for all periods presented as the effect of certain potential common stock equivalents, which consist of stock options and warrants to purchase common stock and restricted stock units, and contingent shares to be issued in the future are anti-dilutive due to the Company’s net loss position. Anti-dilutive common stock equivalents are excluded from diluted net loss per share. The following table sets forth the potential shares of common stock as of the end of each period presented that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share SEPTEMBER 30, 2020 2019 Stock options outstanding 13,709 12,056 Warrants to purchase common stock 30,444 52,647 Restricted stock units outstanding 4,475 1,918 Common shares to be issued in lieu of agent fees 498 498 Employee stock purchase plan 59 65 Maximum contingent consideration shares to be issued 5,972 5,972 55,157 73,156

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of Significant Customer's Revenues and Account Receivable Percentage	Customers to which 10% or more of the Company’s total revenues are attributable for the three months ended September 30, 2020 and 2019 consist of the following: Schedule of Significant Customer's Revenues and Account Receivable Percentage CUSTOMER A B C D E Three months ended September 30, 2020 25% 14% 12% 10% 6% 2019 26% 10% 0% 0% 13% Customers to which 10% or more of the Company’s total revenues are attributable for the nine months ended September 30, 2020 and 2019 consist of the following: CUSTOMER A B C D Nine months ended September 30, 2020 15% 15% 15% 8% 2019 26% 10% 0% 12% Customers to which 10% or more of the Company’s outstanding accounts receivable are attributable as of either September 30, 2020 or December 31, 2019, which may or may not correspond with any of the customers above, consist of the following: CUSTOMER A B C D September 30, 2020 32% 13% 10% 10% December 31, 2019 44% 0% 5% 4%
Schedule of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows (in thousands): Schedule of Cash, Cash Equivalents and Restricted Cash SEPTEMBER 30, DECEMBER 31, Cash and cash equivalents $ 8,971 $ 6,252 Restricted cash 1,560 1,560 Total cash, cash equivalents and restricted cash $ 10,531 $ 7,812
Schedule of Deferred Revenue	Schedule of Deferred Revenue SEPTEMBER 30, 2020 DECEMBER 31, 2019 Product revenues $ 330 $ 299 Financing costs 599 609 License revenues 1,300 1,505 Deferred revenue 2,229 2,413 Less current portion (541 ) (427 ) Deferred revenue, less current portion $ 1,688 $ 1,986
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share SEPTEMBER 30, 2020 2019 Stock options outstanding 13,709 12,056 Warrants to purchase common stock 30,444 52,647 Restricted stock units outstanding 4,475 1,918 Common shares to be issued in lieu of agent fees 498 498 Employee stock purchase plan 59 65 Maximum contingent consideration shares to be issued 5,972 5,972 55,157 73,156

Inventory, net (Tables)

Inventory, net (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories, net consist of the following (in thousands): Schedule of Inventory SEPTEMBER 30, DECEMBER 31, 2020 2019 Raw materials $ 2,162 $ 1,610 Work in progress 896 783 Finished goods 3,135 5,756 Inventories, net $ 6,193 $ 8,149

Right-Of-Use of Assets and Le_2

Right-Of-Use of Assets and Lease Liability (Tables)	9 Months Ended
	Sep. 30, 2020
Right-of-use Of Assets And Lease Liability
Schedule of Components of Lease Expense	The components of lease expense were as follows for each of the comparative three and nine months ended September 30, 2020 and 2019 (in thousands): Schedule of Components of Lease Expense THREE MONTHS ENDED THREE MONTHS ENDED SEPTEMBER 30, 2020 SEPTEMBER 30, 2019 Operating lease cost $ 290 $ 287 Short-term lease cost 38 20 Sublease income (7 ) (25 ) Total operating lease costs $ 321 $ 282 NINE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, 2020 SEPTEMBER 30, 2019 Operating lease cost $ 864 $ 874 Short-term lease cost 109 53 Sublease income (27 ) (73 ) Total operating lease costs $ 946 $ 854
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities for each future calendar year as of September 30, 2020 are as follows (in thousands): Schedule of Maturities of Lease Liabilities OPERATING LEASES 2020, remaining 3 months $ 301 2021 1,231 2022 1,267 2023 1,293 2024 and beyond 867 Total lease payments 4,959 Less: imputed interest 675 Total lease obligation 4,284 Less lease obligation, current portion 981 Lease obligation, non-current portion $ 3,303

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities SEPTEMBER 30, DECEMBER 31, 2020 2019 Accrued compensation $ 3,406 $ 2,730 Accrued warranty costs 487 327 Accrued customer incentives 4,172 5,102 Accrued liabilities, acquisition related 2,126 1,722 Accrued liabilities, other 2,910 2,586 Accrued liabilities, total $ 13,101 $ 12,467
Schedule of Changes in Accrued Warranty Costs	The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amount, as necessary. Changes in the Company’s accrued warranty costs during the period are as follows (in thousands): Schedule of Changes in Accrued Warranty Costs Balance at December 31, 2019 $ 327 Warranties issued (released) during the period 160 Settlements made during the period - Balance at September 30, 2020 $ 487
Schedule of Derivative Liability Measured at Fair Value Using Unobservable Inputs	Schedule of Derivative Liability Measured at Fair Value Using Unobservable Inputs CONTINGENT CONSIDERATION Fair value at December 31, 2019 $ 1,737 Change in estimated fair value recorded of contingent consideration 563 Fair value at September 30, 2020 $ 2,300
Schedule of Fair value of Contingent Consideration Liability	Schedule of Fair value of Contingent Consideration Liability SEPTEMBER 30, DECEMBER 31, 2020 2019 Discount rate 13.9% 15.2% Volatility 49.6% 33.6% Credit spread 12.2% 10.8% Risk-free rate 0.19% 1.66%

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Debt Including Debt to Related Parties	Debt, including debt due to related parties, consists of the following (in thousands): Schedule of Debt Including Debt to Related Parties SEPTEMBER 30, DECEMBER 31, 2020 2019 Secured promissory notes (“October 2012 and April 2013 Secured Promissory Notes”) bearing interest at 8.00% December 31, 2022 $ 3,425 $ 3,425 Secured promissory note (“June 2014 Secured Promissory Note”) bearing interest at prime plus 2% 5.25% payable monthly through June 2036 170 185 8,187 8,404 Secured revolving borrowing (“LSQ Financing”) bearing interest at ( 12.80% November 2020 6,004 3,629 Senior secured promissory notes due to related parties (“August 2015 Senior Secured Promissory Notes”) bearing interest at 8% December 31, 2022 7,300 7,300 Research loan facility (“2018 Research Facility”) bearing interest at 1.00 25 ility beginning on the fourth anniversary of the loan ( September 2022 ), net of imputed interest as of September 30, 2020 of $ 9 . 84 81 Financial institution facility (“2018 Bank Facility”) bearing interest at Euribor plus 2.40% per annum, interest payable monthly and principal payable at maturity ( May 1, 2020 ), 60% guaranteed by Export Credit Agency of Finland for a fee of 2.49% . - 207 Debt, including debt due to related parties 25,000 23,046 Less debt due to related parties, non-current (7,300 ) (7,300 ) Less current portion (6,333 ) (3,899 ) Debt, non-current $ 11,367 $ 11,847
Schedule of Contractual Future Principal Payments	As of September 30, 2020, aggregate contractual future principal payments on the Company’s debt, including debt due to related parties for each calendar year, are due as follows (in thousands): Schedule of Contractual Future Principal Payments Period ended September 30, 2020 Debt Debt to Related Party 2020 $ 6,089 $ - 2021 353 - 2022 2,822 5,000 2023 416 - 2024 436 - Thereafter 6,788 - Total future principal payments 16,904 5,000 Interest payments included in debt balance (1) 975 2,300 $ 17,879 $ 7,300 (1) Due to the debt extinguishment requirements, the Company has included both accrued interest and future interest in the debt balance for certain outstanding debt.
Schedule of Debt Activity	The following table reflects the activity under this note (in thousands): Schedule of Debt Activity 2020 2019 Principal balance, net at December 31, preceding year $ 8,404 $ 8,639 Principal payments (624 ) (545 ) Interest 392 328 Debt discount amortization 15 10 Principal balance, net at September 30, $ 8,187 $ 8,432

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2020
Warrants
Schedule of Fair Value Warrant Assumptions Call Option Exercise	Schedule of Fair Value Warrant Assumptions Call Option Exercise WARRANTS 2020 Expected life (years) 3.01 3.04 Estimated volatility factor 52.9 53.1 % Risk-free interest rate 1.58 1.66 % Expected dividend yield —
Schedule of Fair Value Warrant Assumptions Exchanged Warrants	Schedule of Fair Value Warrant Assumptions Exchanged Warrants EXCHANGED WARRANTS APRIL 2020 WARRANTS Expected life (years) 0.68 3.31 0.38 1.63 Estimated volatility factor 43.0 52.2 % 38.1 46.3 % Risk-free interest rate 0.14 0.26 % 0.10 0.19 % Expected dividend yield — —
Summary of Information About Common Stock Warrants Outstanding	The following table summarizes information about the Company’s common stock warrants outstanding activity through September 30, 2020 (in thousands, except exercise price data): Summary of Information About Common Stock Warrants Outstanding NUMBER OF NINE MONTHS NINE MONTHS ENDED NUMBER NINE MONTHS NUMBER OF SHARES ENDED OF ENDED SHARES SUBJECT TO NUMBER OF WARRANTS OR NUMBER OF SUBJECT TO ISSUE EXPIRATION WARRANTS WARRANTS SHARES WARRANTS WARRANTS DATE DATE EXERCISE ISSUED EXERCISED ISSUED EXCHANGED ISSUED DESCRIPTION MM/YY MM/YY PRICE 12/31/2019 9/30/2020 9/30/2020 9/30/2020 9/30/2020 June 2013 Warrants 06/13 06/23 (1) $ 8.40 27 - - - 27 August 2015 Warrants 08/15 08/23 $ 1.91 4,000 - - (4,000 ) - November 2016 Warrants 11/16 11/26 $ 2.38 125 - - - 125 November 2017 Warrants 06/17 06/27 $ 1.10 80 - - - 80 February 2018 Warrants 1 02/18 12/20 $ 1.00 6,750 - - (1,378 ) 5,372 February 2018 Warrants 2 02/18 12/20 $ 1.25 5,065 - - (4,000 ) 1,065 August 2019 Warrant 09/19 12/21 $ 1.00 20,600 (6,000 ) - (14,600 ) - August 2019 Warrant (Call Option) Various after 08/19 01/23 $ 1.75 16,000 - 6,000 (22,000 ) - April 2020 Warrants, Tranche 1 04/20 05/20 $ 0.75 - (3,393 ) 3,393 - - April 2020 Warrants, Tranche 2 04/20 09/20 $ 0.75 - (2,714 ) 2,714 - - April 2020 Warrants, Tranche 3 04/20 12/20 $ 0.75 - - 13,028 - 13,028 April 2020 Warrants, Tranche 4 04/20 03/21 $ 0.75 - - 5,862 - 5,862 April 2020 Warrants, Tranche 5 04/20 12/21 $ 0.75 - - 4,885 - 4,885 52,647 (12,107 ) 35,882 (45,978 ) 30,444 The weighted average remaining contractual life and exercise price for these warrants is 0.47 0.83 (1) The June 2013 Warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company); or (iii) a sale of all or substantially all of the assets of the Company unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise), hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.

Share-Based Plans (Tables)

Share-Based Plans (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Assumptions Utilized in Option Pricing Model	Schedule of Assumptions Utilized in Option Pricing Model AUGUST 3, 2020 Expected life (years) 2.14 6.08 Estimated volatility factor 58.8 % Risk-free interest rate 0.28 % Expected dividend yield —
Summary of Stock Options Activity	The following table summarizes the activity of stock options from December 31, 2019 to September 30, 2020 (in thousands, except weighted average exercise price): Summary of Stock Options Activity WEIGHTED- AVERAGE EXERCISE OPTIONS PRICE Balance at December 31, 2019 11,821 $ 2.53 Options granted 2,612 1.16 Options exercised (36 ) 0.87 Options cancelled (688 ) 1.90 Balance at September 30, 2020 13,709 2.30
Summary of Restricted Stock Units Activity	The following table summarizes the activity of restricted stock units from December 31, 2019 to September 30, 2020 (in thousands, except weighted average grant date fair value): Summary of Restricted Stock Units Activity WEIGHTED- RESTRICTED AVERAGE STOCK EXERCISE UNITS PRICE Outstanding at December 31, 2019 2,405 $ 1.40 Granted 2,742 0.96 Exercised (647 ) 1.23 Forfeited (25 ) 1.37 Outstanding at September 30, 2020 4,475 $ 1.14
Summary of Non-vested Restricted Stock Units Activity	The following table summarizes the activity of non-vested restricted stock units from December 31, 2019 to September 30, 2020 (in thousands, except weighted average grant date fair value): Summary of Non-vested Restricted Stock Units Activity WEIGHTED AVERAGE GRANT SHARES DATE FAIR OUTSTANDING VALUE Nonvested at December 31, 2019 711 $ 1.45 Granted 2,742 $ 0.96 Vested (1,951 ) $ 1.00 Forfeited (25 ) $ 1.37 Nonvested at September 30, 2020 1,477 $ 1.15

Summary of Business, Basis of_2

Summary of Business, Basis of Presentation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 15, 2021	Mar. 15, 2021	Dec. 15, 2020	Nov. 06, 2020	Apr. 30, 2020	Apr. 29, 2020	Dec. 31, 2019	Sep. 30, 2019
SummaryofBusinessBasisofPresentation [Line Items]
Date of incorporation	Jun. 15, 2006
Accumulated deficit	$ 336,606							$ 320,649
Working capital surplus	1,066
Cash and cash equivalents	8,971							6,252
Debt excluding related parties	17,700
Debt due to related parties	7,300							$ 7,300
Restricted cash	$ 1,560
Warrants to purchase of common stock shares	30,444							52,647
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Warrant Exchange Agreement [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants to purchase of common stock shares							45,977,809
Warrant Exchange Agreement [Member] | Prior Warrants [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants to purchase of common stock shares						45,977,809
Warrant Exchange Agreement [Member] | New Warrants [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants to purchase of common stock shares						29,881,855
Warrant Exchange Agreement [Member] | New Warrants [Member] | Five Tranches [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.75
Warrant Exchange Agreement [Member] | New Warrants [Member] | Share-based Payment Arrangement, Tranche One [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants to purchase of common stock shares	6,106,646
Warrant Exchange Agreement [Member] | New Warrants [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Forecast [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants to purchase of common stock shares				13,027,512
Warrant Exchange Agreement [Member] | New Warrants [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Forecast [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants to purchase of common stock shares			5,862,380
Warrant Exchange Agreement [Member] | New Warrants [Member] | Tranche Four [Member] | Forecast [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants to purchase of common stock shares		4,885,317
Warrant Exchange Agreement [Member] | New Warrants [Member] | Remaining Tranche Four [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Warrants and Rights Outstanding	$ 17,800
Subsequent Event [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Cash and cash equivalents					$ 5,574
Pro Farm Technogies Comercio de Insumos Agricolas do Brasil ltda [Member]
SummaryofBusinessBasisofPresentation [Line Items]
Ownership controlling interest percentage									99.00%

Schedule of Significant Custome

Schedule of Significant Customer's Revenues and Account Receivable Percentage (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Customer A [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable	25.00%	26.00%	15.00%	26.00%
Customer A [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable			32.00%		44.00%
Customer B [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable	14.00%	10.00%	15.00%	10.00%
Customer B [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable			13.00%		0.00%
Customer C [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable	12.00%	0.00%	15.00%	0.00%
Customer C [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable			10.00%		5.00%
Customer D [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable	10.00%	0.00%	8.00%	12.00%
Customer D [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable			10.00%		4.00%
Customer E [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues and accounts receivable	6.00%	13.00%

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 8,971	$ 6,252
Restricted cash	1,560	1,560
Total cash, cash equivalents and restricted cash	$ 10,531	$ 7,812	$ 9,459	$ 19,781

Schedule of Deferred Revenue (D

Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Product revenues	$ 330	$ 299
Financing costs	599	609
License revenues	1,300	1,505
Deferred revenue	2,229	2,413
Less current portion	(541)	(427)
Deferred revenue, less current portion	$ 1,688	$ 1,986

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per share	55,157,000	73,156,000
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per share	13,709,000	12,056,000
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per share	30,444,000	52,647,000
Restricted Stock Units Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per share	4,475,000	1,918,000
Common Shares to be Issued in Lieu of Agent Fees [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per share	498,000	498,000
Stock Options Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per share	59,000	65,000
Maximum Ccontingent Consideration Shares To Be Issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earning per share	5,972,000	5,972,000

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2020Number	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)
Product Information [Line Items]
Concentration risk, supplier				The active ingredient in the Company’s Regalia product line is derived from the giant knotweed plant, which the Company obtains from China. The Company currently relies on one supplier for this plant. Such single supplier acquires raw knotweed from numerous regional sources and performs an extraction process on this plant, creating a dried extract that is shipped to the Company’s manufacturing plant.
Ownership in an indirect vendor/supplier relationship percentage	12.00%			12.00%
Research and Development Expense	$ 2,860,000	$ 3,473,000		$ 7,816,000	$ 9,490,000
Patent Expenses	252,000	287,000		842,000	846,000
[custom:ResearchAndDevelopmentExpensesAndPatentExpensesOffsetingValue]				702,000
Shipping and handling costs	435,000	281,000		1,153,000	998,000
Advertising costs	186,000	173,000		476,000	548,000
Depreciation expense	298,000	359,000		903,000	1,262,000
Amortization expense	$ 587,000	$ 165,000		$ 1,763,000	$ 165,000
Operating segment | Number			1
Revenue Benchmark [Member] | International [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues	26.00%	11.00%		26.00%	8.00%
Revenue Benchmark [Member] | Four Product [Member] | International [Member]
Product Information [Line Items]
Customers accounted for percentage of company's total revenues	78.00%	85.00%		85.00%	91.00%
Maximum [Member]
Product Information [Line Items]
Receivables due period				120 days

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 2,162	$ 1,610
Work in progress	896	783
Finished goods	3,135	5,756
Inventories, net	$ 6,193	$ 8,149

Inventory, net (Details Narrati

Inventory, net (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Inventory valuation reserves	$ 353,000		$ 353,000		$ 248,000
Inventory, finished goods	3,135,000		3,135,000		$ 5,756,000
Amortization expense	587,000	$ 165,000	1,763,000	$ 165,000
Inventory adjustments	600,000	$ 317,000	1,230,000	$ 643,000
Paycheck Protection Program [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization expense	109,000		109,000
Paycheck Protection Program [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Inventory, finished goods	$ 217,000		$ 217,000

Schedule of Components of Lease

Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Right-of-use Of Assets And Lease Liability
Operating lease cost	$ 290	$ 287	$ 864	$ 874
Short-term lease cost	38	20	109	53
Sublease income	(7)	(25)	(27)	(73)
Total operating lease costs	$ 321	$ 282	$ 946	$ 854

Schedule of Maturities of Lease

Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Right-of-use Of Assets And Lease Liability
2020, remaining 3 months	$ 301
2021	1,231
2022	1,267
2023	1,293
2024 and beyond	867
Total lease payments	4,959
Less: imputed interest	675
Total lease obligation	4,284
Less lease obligation, current portion	981	$ 913
Lease obligation, non-current portion	$ 3,303	$ 3,970

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued compensation	$ 3,406	$ 2,730
Accrued warranty costs	487	327
Accrued customer incentives	4,172	5,102
Accrued liabilities, acquisition related	2,126	1,722
Accrued liabilities, other	2,910	2,586
Accrued liabilities, total	$ 13,101	$ 12,467

Accrued Liabilities (Details Na

Accrued Liabilities (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Product Warranty Expense	$ 19,000	$ 75,500	$ 241,000	$ 245,000
Reduced warranty expense		29,000	81,000	$ 173,000
Accrued liabilities	1,006,000		1,006,000
Other liabilities	1,294,000		$ 1,294,000
Warranty Claims [Member]
SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]
Reduced warranty expense	$ 0	$ 29,000

Schedule of Changes in Accrued

Schedule of Changes in Accrued Warranty Costs (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Payables and Accruals [Abstract]
Balance at December 31, 2019	$ 327
Warranties issued (released) during the period	160
Settlements made during the period
Balance at September 30, 2020	$ 487

Schedule of Derivative Liabilit

Schedule of Derivative Liability Measured at Fair Value Using Unobservable Inputs (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Payables and Accruals [Abstract]
Fair value at December 31, 2019	$ 1,737
Change in estimated fair value recorded of contingent consideration	563
Fair value at September 30, 2020	$ 2,300

Schedule of Fair value of Conti

Schedule of Fair value of Contingent Consideration Liability (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Discount rate	13.90%	15.20%
Volatility	49.60%	33.60%
Credit spread	12.20%	10.80%
Risk-free rate	0.19%	1.66%

Schedule of Debt Including Debt

Schedule of Debt Including Debt to Related Parties (Details) (Parenthetical) - Secured Debt [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2020
Secured Promissory Notes Interest Rate At Eight Percent [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	8.00%		8.00%
Debt instrument, maturity date	Dec. 31, 2022	Dec. 31, 2022
June 2014 Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	5.25%
Debt instrument, prime rate		2.00%
Debt instrument, payment terms	payable monthly through June 2036	payable monthly through June 2036
Debt instrument, maturity date discription	June 2036	June 2036
Unamortized debt discount	$ 170	$ 185
Secured Revolving Borrowing Interest Rate At Twelve Point Eighty Percent Through May Two Thousand Twenty [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	12.80%	12.80%
Debt instrument, payment terms	November 2020	November 2020
Senior Secured Promissory Note Interest Rate At Eight Percent [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	8.00%	8.00%
Debt instrument, maturity date	Dec. 31, 2022	Dec. 31, 2022
Research Loan Facility Interest Rate At One Percent [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	1.00%	1.00%
Debt instrument principal payment	25.00%	25.00%
Debt Instrument, Maturity Date, Description	September 2022	September 2022
Unamortized debt discount	$ 9
Two Thousand And Eighteen Bank Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate		2.49%
Debt instrument, maturity date		May 1, 2020
Debt instrument, prime rate		2.40%
Export Credit Agency of Finland for a Fee of 2.49% [Member]
Debt Instrument [Line Items]
Debt instrument, guarantee		60.00%

Schedule of Debt Including De_2

Schedule of Debt Including Debt to Related Parties (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2020
Debt Instrument [Line Items]
Less debt due to related parties, non-current	$ (7,300)	$ (7,300)
Debt, non-current	11,367	11,847
Secured Debt [Member]
Debt Instrument [Line Items]
Debt, including debt due to related parties	25,000	23,046
Less debt due to related parties, non-current	(7,300)	(7,300)
Less current portion	(6,333)	(3,899)
Debt, non-current	11,367	11,847
Secured Debt [Member] | Secured Promissory Notes Interest Rate At Eight Percent [Member]
Debt Instrument [Line Items]
Debt, including debt due to related parties	$ 3,425	3,425
Debt Instrument, Interest Rate, Stated Percentage	8.00%		8.00%
Secured Debt [Member] | June 2014 Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt, including debt due to related parties	$ 8,187	8,404
Debt Instrument, Interest Rate, Stated Percentage	5.25%
Secured Debt [Member] | Secured Revolving Borrowing Interest Rate At Twelve Point Eighty Percent Through May Two Thousand Twenty [Member]
Debt Instrument [Line Items]
Debt, including debt due to related parties	$ 6,004	$ 3,629
Debt Instrument, Interest Rate, Stated Percentage	12.80%	12.80%
Secured Debt [Member] | Senior Secured Promissory Note Interest Rate At Eight Percent [Member]
Debt Instrument [Line Items]
Debt, including debt due to related parties	$ 7,300	$ 7,300
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Secured Debt [Member] | Research Loan Facility Interest Rate At One Percent [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.00%	1.00%
Debt instrument principal payment	25.00%	25.00%
Debt Instrument, Maturity Date, Description	September 2022	September 2022
Secured Debt [Member] | Research Loan Facility Interest Rate At One Percent [Member]
Debt Instrument [Line Items]
Debt, including debt due to related parties	$ 84	$ 81
Secured Debt [Member] | Two Thousand And Eighteen Bank Facility [Member]
Debt Instrument [Line Items]
Debt, including debt due to related parties	$ 0	$ 207
Debt Instrument, Interest Rate, Stated Percentage		2.49%

Schedule of Contractual Future

Schedule of Contractual Future Principal Payments (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Debt [Line Items]
Total future principal payments	$ 16,904
Interest payments included in debt balance	975	[1]
Debt instrument, periodic payment	17,879
Related Party [Member]
Debt [Line Items]
Total future principal payments	5,000
Interest payments included in debt balance	2,300	[1]
Debt instrument, periodic payment	7,300
2020 [Member]
Debt [Line Items]
Total future principal payments	6,089
2020 [Member] | Related Party [Member]
Debt [Line Items]
Total future principal payments
2021 [Member]
Debt [Line Items]
Total future principal payments	353
2021 [Member] | Related Party [Member]
Debt [Line Items]
Total future principal payments
2022 [Member]
Debt [Line Items]
Total future principal payments	2,822
2022 [Member] | Related Party [Member]
Debt [Line Items]
Total future principal payments	5,000
2023 [Member]
Debt [Line Items]
Total future principal payments	416
2023 [Member] | Related Party [Member]
Debt [Line Items]
Total future principal payments
2024 [Member]
Debt [Line Items]
Total future principal payments	436
2024 [Member] | Related Party [Member]
Debt [Line Items]
Total future principal payments
Thereafter [Member]
Debt [Line Items]
Total future principal payments	6,788
Thereafter [Member] | Related Party [Member]
Debt [Line Items]
Total future principal payments
[1]	Due to the debt extinguishment requirements, the Company has included both accrued interest and future interest in the debt balance for certain outstanding debt.

Schedule of Debt Activity (Deta

Schedule of Debt Activity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Short-term Debt [Line Items]
Principal payments	$ (16,904)
Commitments And Contingencies [Line Items]
Short-term Debt [Line Items]
Principal balance, net at December 31, prededing year	8,404	$ 8,639
Principal payments	(624)	(545)
Interest	392	328
Debt discount amortization	15	10
Principal balance, net at September 30,	$ 8,187	$ 8,432

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	Jan. 31, 2020	Jan. 30, 2020	Jun. 30, 2014	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Required deposit balance				$ 1,560,000		$ 1,560,000			$ 1,560,000
Interest expense				405,000	$ 355,000	1,073,000	$ 1,014,000
L S Q Funding Group L C [Member]
Debt Instrument [Line Items]
Outstanding principal amount				6,004,000		6,004,000
Sale of certain accounts receivable to third-party		$ 7,000,000
Interest expense				188,000	121,000	$ 454,000	303,000
L S Q Funding Group L C [Member] | Maximum [Member]
Debt Instrument [Line Items]
Sale of certain accounts receivable to third-party	$ 20,000,000
Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument description						Under this note the Company is required to maintain a current ratio of not less than 1.25-to-1.0, a debt-to-worth ratio of no greater than 4.0-to-1.0 and a loan-to-value ratio of no greater than 70% as determined by Five Star Bank.
Invoice Purchase Agreement [Member] | L S Q Funding Group L C [Member]
Debt Instrument [Line Items]
Debt instrument description	In January 2020, the Company entered into a Second Amendment to the Company’s Invoice Purchase Agreement with LSQ. The amendment, among other things, (i) increased the amount of eligible customer invoices which LSQ may elect to purchase from the Company to up to $20,000,000 of eligible customer invoices from the Company from $7,000,000; (ii) increased the advance rate to 90% from 85% and 70% from 60%, respectively, of the face value of domestic and international receivables being sold; (iii) decreased the invoice purchase fee rate from 0.40% to 0.25%; (iv) increased the funds usage fee from 0.020% to 0.025%; (v) extended the 0% aging and collection fee percentage charged at the time when the purchased invoice is collected from 90 days to 120 days, and increased the fee percentage charged thereafter from 0.35% to 0.75%; and (vi) decreased the early termination fee from 0.75% to 0.50%.
Percentage Of Common Stock Outstanding To Increase Shares Reserved For Issuance | L S Q Funding Group L C [Member]
Debt Instrument [Line Items]
Invoice purchase fee percentage	90.00%	85.00%
International Receivables [Member] | L S Q Funding Group L C [Member]
Debt Instrument [Line Items]
Invoice purchase fee percentage	70.00%	60.00%
Amended Inventory Financing Addendum [Member] | L S Q Funding Group L C [Member]
Debt Instrument [Line Items]
Debt instrument description	In addition to the Amendment, the Company simultaneously entered into an Amended Inventory Financing Addendum (the “Addendum”) with LSQ. The Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company’s unpaid finished goods inventory; (ii) 65% of the appraised value of the Company’s inventory performed on or on behalf of LSQ; or (iii) $3,000,000. Funds advance under the Addendum are subject to a monthly inventory management fee of 0.5% on the average monthly inventory funds available and a daily interest rate of 0.025%.
October 2012 and April 2013 Secured Promissory Notes [Member]
Debt Instrument [Line Items]
Outstanding principal amount				2,450,000		$ 2,450,000
Due to promissory note				3,425,000		3,425,000
Accrued interest				975,000		975,000
Secured promissory notes				$ 533,000	$ 337,000	$ 533,000	$ 337,000
June 2014 Secured Promissory Note [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate				5.25%		5.25%
June 2014 Secured Promissory Note [Member] | Business Loan Agreement [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument borrowing amount			$ 10,000,000
Debt instrument, interest rate								5.25%
Required deposit balance								$ 1,560,000
June 2014 Secured Promissory Note [Member] | Business Loan Agreement [Member] | Secured Debt [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate								2.00%

Schedule of Fair Value Warrant

Schedule of Fair Value Warrant Assumptions Call Option Exercise (Details)	Sep. 30, 2020Number
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	3 years 3 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	3 years 14 days
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	52.9
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	53.1
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.58
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.66
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input

Schedule of Fair Value Warran_2

Schedule of Fair Value Warrant Assumptions Exchanged Warrants (Details)	Sep. 30, 2020Number
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	3 years 3 days
Measurement Input, Expected Term [Member] | Minimum [Member] | Exchanged Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	8 months 4 days
Measurement Input, Expected Term [Member] | Minimum [Member] | April Two Thousand Twenty Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	4 months 17 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	3 years 14 days
Measurement Input, Expected Term [Member] | Maximum [Member] | Exchanged Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	3 years 3 months 21 days
Measurement Input, Expected Term [Member] | Maximum [Member] | April Two Thousand Twenty Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding term	1 year 7 months 17 days
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	52.9
Measurement Input, Price Volatility [Member] | Minimum [Member] | Exchanged Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	43
Measurement Input, Price Volatility [Member] | Minimum [Member] | April Two Thousand Twenty Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	38.1
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	53.1
Measurement Input, Price Volatility [Member] | Maximum [Member] | Exchanged Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	52.2
Measurement Input, Price Volatility [Member] | Maximum [Member] | April Two Thousand Twenty Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	46.3
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.58
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Exchanged Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.14
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | April Two Thousand Twenty Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.10
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.66
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Exchanged Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.26
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | April Two Thousand Twenty Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.19
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input
Measurement Input, Expected Dividend Rate [Member] | Exchanged Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input
Measurement Input, Expected Dividend Rate [Member] | April Two Thousand Twenty Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input

Summary of Information About Co

Summary of Information About Common Stock Warrants Outstanding (Details) - $ / shares		9 Months Ended
		Sep. 30, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Exercise price		$ 0.75
Number of shares subject to warrants issued		30,444	52,647
Number of warrants exchanged		(45,978)
Number of Warrants Excercised		(12,107)
Number of warrants or shares issued		35,882
June 2013 Warrant [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2013-06
Class Of Warrants Expiration Month And Year	[1]	2023-06
Exercise price		$ 8.40
Number of shares subject to warrants issued		27	27
August 2015 Warrant [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2015-08
Class Of Warrants Expiration Month And Year		2023-08
Exercise price		$ 1.91
Number of shares subject to warrants issued			4,000
Number of warrants exchanged		(4,000)
November 2016 Warrant [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2016-11
Class Of Warrants Expiration Month And Year		2026-11
Exercise price		$ 2.38
Number of shares subject to warrants issued		125	125
November 2017 Warrants [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2017-06
Class Of Warrants Expiration Month And Year		2027-06
Exercise price		$ 1.10
Number of shares subject to warrants issued		80	80
February 2018 Warrants 1 [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2018-02
Class Of Warrants Expiration Month And Year		2020-12
Exercise price		$ 1
Number of shares subject to warrants issued		5,372	6,750
Number of warrants exchanged		(1,378)
February 2018 Warrants 2 [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2018-02
Class Of Warrants Expiration Month And Year		2020-12
Exercise price		$ 1.25
Number of shares subject to warrants issued		1,065	5,065
Number of warrants exchanged		(4,000)
August 2019 Warrants [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2019-09
Class Of Warrants Expiration Month And Year		2021-12
Exercise price		$ 1
Number of shares subject to warrants issued			20,600
Number of warrants exchanged		(14,600)
Number of Warrants Excercised		(6,000)
Various Dates Starting in August 2019 [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2019-08
Class Of Warrants Expiration Month And Year		2023-01
Exercise price		$ 1.75
Number of shares subject to warrants issued			16,000
Number of warrants exchanged		(22,000)
Number of warrants or shares issued		6,000
April 2020 Warrants Tranche One [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2020-04
Class Of Warrants Expiration Month And Year		2020-05
Exercise price		$ 0.75
Number of Warrants Excercised		(3,393)
Number of warrants or shares issued		3,393
April 2020 Warrants Tranche Two [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2020-04
Class Of Warrants Expiration Month And Year		2020-09
Exercise price		$ 0.75
Number of Warrants Excercised		(2,714)
Number of warrants or shares issued		2,714
April 2020 Warrants Tranche Three [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2020-04
Class Of Warrants Expiration Month And Year		2020-12
Exercise price		$ 0.75
Number of shares subject to warrants issued		13,028
Number of warrants or shares issued		13,028
April 2020 Warrants Tranche Four [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2020-04
Class Of Warrants Expiration Month And Year		2021-03
Exercise price		$ 0.75
Number of shares subject to warrants issued		5,862
Number of warrants or shares issued		5,862
April 2020 Warrants Tranche Five [Member]
Class of Warrant or Right [Line Items]
Class Of Warrants Issuance Month And Year		2020-04
Class Of Warrants Expiration Month And Year		2021-12
Exercise price		$ 0.75
Number of shares subject to warrants issued		4,885
Number of warrants or shares issued		4,885
[1]	The June 2013 Warrants expire upon the earlier to occur of (i) the date listed above; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any transfer of more than 50% of the voting power of the Company, reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose of changing the domicile of the Company); or (iii) a sale of all or substantially all of the assets of the Company unless the Company’s stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise), hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	Aug. 06, 2019	Dec. 31, 2019	Sep. 30, 2020	Dec. 15, 2021	Mar. 15, 2021	Dec. 15, 2020	Sep. 15, 2020	May 01, 2020	Apr. 29, 2020	Mar. 31, 2020	Feb. 29, 2020
Class of Warrant or Right [Line Items]
Warrants expiration date description			On August 6, 2019, the Company entered into a warrant amendment and plan of reorganization agreement (“Warrant Reorganization Agreement”) with certain holders of the February 2018 Warrants. Pursuant to the Warrant Reorganization Agreement, the Company agreed to extend the expiration date under the February 2018 Warrants held by such holders from December 2020 to December 2021
Warrants to purchase of common stock shares		52,647	30,444
Warrant exercise price			$ 0.75
Warrant weighted average remaining contractual life			5 months 19 days
August Two Thousand Nineteen Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock shares		6,000,000
Number of shares issued during period		6,000,000
Fair vaue of warrants		$ 1,391,000
February Two Thousand And Eighteen [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock shares		16,000,000									6,000,000
April Two Thousand Twenty Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock shares								3,392,581
April Two Thousand Twenty Warrants [Member] | Forecast [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock shares				4,885,317	5,862,380	13,027,512	2,714,065
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price			$ 0.83
Warrant Reorganization Agreement [Member] | February Two Thousand Eighteen Warrants One [Member]
Class of Warrant or Right [Line Items]
Stock trades price per share	$ 1
Warrants to purchase of common stock shares										6,000,000
Warrant Reorganization Agreement [Member] | August Two Thousand Nineteen Warrants [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Number of warrants exercised	36,600,000
Warrant Exchange Agreement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock shares									45,977,809
Warrant Exchange Agreement [Member] | April Two Thousand Twenty Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase of common stock shares									29,881,855

Schedule of Assumptions Utilize

Schedule of Assumptions Utilized in Option Pricing Model (Details)	Aug. 03, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	58.80%
Risk-free interest rate	0.28%
Expected dividend yield
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	2 years 1 month 20 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	6 years 29 days

Summary of Stock Options Activi

Summary of Stock Options Activity (Details) - $ / shares	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Number of Options, beginning balance				11,821,000
Weighted Average Exercise Price, ending balance				$ 2.53
Number of Options granted		2,612,000	5,363,000	2,612,000
Weighted Average Exercise Price, granted		$ 1.16	$ 1.43	$ 1.16
Number of Options exercised	(225,000)	(19,000)	(13,000)	(36,000)
Weighted Average Exercise Price, exercised	$ 0.71	$ 0.90	$ 1.16	$ 0.87
Number of Options cancelled				(688,000)
Weighted Average Exercise Price, cancelled				$ 1.90
Number of Options, ending balance		13,709,000		13,709,000
Weighted Average Exercise Price, ending balance		$ 2.30		$ 2.30

Summary of Restricted Stock Uni

Summary of Restricted Stock Units Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Restricted stock units, Ending Balance | shares	2,405,000
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 1.40
Restricted stock units, Granted | shares	2,742,000
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 0.96
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | shares	(647,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 1.23
Restricted stock units, Forfeited | shares	(25,000)
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	$ 1.37
Restricted stock units, Ending Balance | shares	4,475,000
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 1.14

Summary of Non-vested Restricte

Summary of Non-vested Restricted Stock Units Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, Granted | shares	2,742,000
Weighted Average Grant Date Fair Value, Granted	$ 0.96
Restricted stock units, Vested | shares	(647,000)
Weighted Average Grant Date Fair Value, Vested	$ 1.23
Weighted Average Grant Date Fair Value, Forfeited	$ 1.37
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, Ending Balance | shares	711,000
Weighted Average Grant Date Fair Value, Ending Balance	$ 1.45
Restricted stock units, Granted | shares	2,742,000
Weighted Average Grant Date Fair Value, Granted	$ 0.96
Restricted stock units, Vested | shares	(1,951,000)
Weighted Average Grant Date Fair Value, Vested	$ 1
Restricted stock units, Forfeited | shares	(25,000)
Weighted Average Grant Date Fair Value, Forfeited	$ 1.37
Restricted stock units, Ending Balance | shares	1,477,000
Weighted Average Grant Date Fair Value, Ending Balance	$ 1.15

Share-Based Plans (Details Narr

Share-Based Plans (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended					9 Months Ended
	Aug. 31, 2020	May 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense			$ 946,000			$ 742,000
Number of options outstanding			13,709,000					13,709,000		11,821,000
Number of restricted stock units outstanding			4,475,000					4,475,000
Number of shares available for grant			288,000					288,000
Stock based compensation expense								$ 2,699,000	$ 1,888,000
Weighted Average Exercise Price, Options exercised		$ 0.71	$ 0.90			$ 1.16		$ 0.87
Number of option granted to purchase common stock			2,612,000			5,363,000		2,612,000
Number of options weighted-average exercise price granted			$ 1.16			$ 1.43		$ 1.16
Number of options exercised		225,000	19,000			13,000		36,000
Stock Issued During Period, Value, Employee Stock Purchase Plan			$ 50,000	$ 45,000	$ 84,000	$ 57,000	$ 23,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options exercised		$ 0.71
Stock Issued During Period, Shares, Employee Stock Purchase Plans		890,000
Stock Issued During Period, Value, Employee Stock Purchase Plan		$ 632,000
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 2,450,000
Weighted Average Exercise Price, Options exercised	$ 1.16
Fair value of option	$ 899,000
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	1,250,000
Stock Options Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of purchase price of share on fair market value of share			85.00%					85.00%
Stock based compensation expense			$ 18,000			$ 13,000		$ 55,000	$ 18,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	5 Months Ended	9 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	May 30, 2020	May 01, 2020	Apr. 29, 2020	Sep. 30, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares		52,647	30,444
April Two Thousand Twenty Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares					3,392,581
August Two Thousand Nineteen Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares		6,000,000
Stock Issued During Period, Shares, New Issues		6,000,000
August 2020 Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares	6,000,000
Stock Issued During Period, Shares, New Issues	6,000,000
Ospraie [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares	5,027,325
Stock Issued During Period, Shares, New Issues			4,441,979
Ospraie [Member] | April Two Thousand Twenty Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares			21,736,081
Waddell And Reed [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues			694,242
Waddell And Reed [Member] | August Two Thousand Nineteen Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares			3,397,157
Ardsley [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares	874,314
Stock Issued During Period, Shares, New Issues			722,517
Ardsley [Member] | August 2020 Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares			3,780,185
August 2015 Senior Secured Promissory Notes [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Beneficial ownership interest percentage			40.00%
Debt Instrument, Face Amount			$ 5,000,000
Notes Payable, Related Parties, Current			7,300,000
Interest Payable			2,300,000
Secured Debt			$ 1,399,000				$ 988,000
Warrant Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares						45,977,809
Warrant Exchange Agreement [Member] | April Two Thousand Twenty Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares						29,881,855
Warrant Exchange Agreement [Member] | August 2020 Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares			2,714,065	3,392,581
Warrant Exchange Agreement [Member] | Ospraie [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Beneficial ownership interest percentage			41.70%
Warrants to purchase of common stock shares			30,666,667
Warrant Exchange Agreement [Member] | Waddell And Reed [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Beneficial ownership interest percentage			17.90%
Warrants to purchase of common stock shares			8,000,000
Warrant Exchange Agreement [Member] | Ardsley [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Beneficial ownership interest percentage			11.10%
Warrants to purchase of common stock shares			5,222,333
Warrant Reorganization Agreement [Member] | February Two Thousand Eighteen Warrants One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase of common stock shares	6,000,000

Other Matters (Details Narrativ

Other Matters (Details Narrative) - USD ($)	Nov. 09, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 21, 2020	Apr. 30, 2020
Other Commitments [Line Items]
Notes amount					$ 1,723,000
Research and development expenses and patent expenses		$ 702,000
Research and development expenses and patent expenses			$ 695,000
Capitalized inventory costs			326,000
[custom:AmortizedOffsettingCostOfProductRevenues]			109,000
[custom:FuturePeriodInCostOfProductRevenue]			$ 217,000
Chief Financial Officer [Member]
Other Commitments [Line Items]
Payments of salary				$ 330,000
Chief Financial Officer [Member] | Consulting Agreement [Member] | Subsequent Event [Member]
Other Commitments [Line Items]
Stock issued during the period rsus	200,000